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ABSTRACT  
 
Background. Breast cancer is the most commonly occurring cancer in the 
females and the leading cause of cancer deaths in Vietnamese women. Beside the 
traditional histopathological classification according to the WHO, the genetic and 
molecular findings in the last decades have introduced a new nomenclature to 
identify of breast cancers oriented mostly to the functional characteristics of the 
neoplastic cells and the needs of therapy. Based on these criteria, breast cancers are 
divided into five main groups according to the expression levels of biomarkers  such 
as estrogen (ER), progesterone receptors (PR), proliferation index (Ki67) and 
human epidermal growth factor receptor 2 (HER2). Among them, HER2 protein 
overexpression and gene amplification have a particularly important role to play in 
the classification of molecular subtypes. It is also a significant biomarker which has 
prognostic and predictive value and is a goal of targeted therapy. 
The aim of this study was to identify the prevalence rate of HER2 gene 
amplification or overexpression in the local Vietnamese population, and determine 
the molecular subtypes of breast cancer. 
Materials and methods. Paraffin tissue blocks from 88 Vietnamese women 
diagnosed consecutively with invasive primary breast carcinoma during a period of 
12 months, from April 2016 to April 2017. These blocks underwent 
immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) and 
dual in situ hybridization (DISH) for the assessment of HER2 status. HER2 positive 
includes the HER2 (3+) score in IHC or the HER2 gene amplification in FISH. The 
IHC for ER, PR and Ki67 were also evaluated to determine molecular subtypes. The 
analyses were based on the guideline of ASCO/CAP 2013. 
Results. The median age of patients was 52.5. By using IHC, 30.7 % of 
tumours were strongly expressed in (3+) score the HER2 protein. The HER2 
equivocal results occupied 9.1%. Gene amplification by FISH was found in 25% of 
tumours with an equivocal score in IHC. The prevalence rate of HER2 positive was 
32.9%. The concordance between IHC and DISH assay were 100% in case of IHC 
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positive or negative. In case HER2 results by using immunohistochemistry 
technique were equivocal, DISH was able to identify 2 cases (25% of cases) as 
positive. The concordance between FISH and DISH in the equivocal cases (8 cases) 
was 100%. Luminal B subtype accounted for the highest proportion, at 37.5% 
whereas luminal A was the lowest, at 18.2%. The HER2 enriched and triple 
negative subtype occupied 22.7% and 21.6%, respectively. A significant 
relationship was found between HER2 status as well as molecular subtypes and 
some clinicopathological characteristics and biomarkers. 
Conclusion. HER2 gene amplification was found in 32.9% of Vietnamese 
breast cancers. This prevalence was considerably higher than in published studies 
on women from Western countries. Luminal B subtype was the most frequent, at 
37.5% while the uncommon belonged to luminal A, at 18.2%. The HER2 enrich and 
triple negative subtypes were fairly higher than that in literature. HER2 status as 
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1. INTRODUCTION 
 
1.1. Breast Cancer 
Breast cancer (BC) is currently the most common cancer in women 
worldwide. The incidence and the mortality of breast cancer continues to increase 
rapidly in most countries, with over 2 million new cancer cases diagnosed and 
approximately 600,000 cancer deaths in 2018 [1]. However, in the USA, the last 
decade (2005-2014) witnessed a stability in the incidence rate and a decline in the 
mortality rate (2006-2015) as a result of the earlier diagnosis following the 
implementation of screening programs and the access to the new therapies [2]. The 
estimated incidence and the mortality rates of breast cancer vary across 
communities and countries. The global age-standardized  incidence rate (ASR) 
of breast cancer is 46.3 per 100,000 women and the mortality incidence rate is 
13.0 per 100,000 women [1]. 
 
Figure 1.1. Estimated age -standardized incidence and mortality rate in 2018, 
worldwide, females [1]. 
In Vietnam, breast cancer ranks the first in the list of common cancers in 
women. The last decade has witnessed an increase in the incidence of breast 
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cancer, with 15,229 newly-diagnosed cases having been reported, occupying 
20.6% of all cancers in women. The ASR of breast cancer in Vietnam is 
around 26.4 per 100,000 women in 2018 compared to 23.0 in 2012 [3]. 
However, breast cancer has a high mortality rate, accounting for 6,103 deaths in 
2018 and occupying approximately 14% of all deaths in women and the first- 
leading cause of death for cancer among Vietnamese women. [1].  
 
Figure 1.2. Estimated age -standardized incidence and mortality rate in 2018, 
Vietnam, females [1] 
Nowadays, the effectiveness of treatment and screening program generally 
aid in improving breast cancer survival time and its prognosis. However, this type 
of cancer is a clinically heterogeneous disease. In clinical settings, therefore, 
although patient might have the same histopathological characteristics or histologic 
stages, there are variations in their clinical manifestations, progresses, responses to 
treatments and prognoses [4]. Various molecular studies have been performed 
during the last decades to enhance a better understanding of tumor carcinogenesis 
and to determine the biological properties of tumor cells. These studies have shown 
that although breast cancer has the same histologic types and grades, it is not the 
unique group. A number of researchers have found that breast carcinoma is 
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composed of multiple molecular subtypes [5]. These subtypes of breast cancer 
might differ in risk-factor epidemiology, in the progression of the disease and in the 
response to therapy [6]. The classification of molecular subtypes is very useful in 
terms of deciding optimal adjuvant treatment and determining accurate prognosis 
for breast cancer. According to the 13th St Gallen International Breast Cancer 
Conference (2013), BC was classified into five main subtypes  including luminal A, 
luminal B-HER2 negative, luminal B-HER2 positive, HER2 enrich and triple 
negative. This classification was made based on biomarkers expressions such as 
HER2, ER, PR, Ki67 in immunohistochemistry (IHC) and the amplification of 
HER2 gene in in situ hybridization (ISH). The treatment and prognosis is absolutely 
different among the subtypes. 
Many studies have shown that the amplification of the HER2/neu proto-
oncogene or HER2 protein overexpression has an important role to play in this 
disease. It is also an important biomarker which has prognostic and predictive value 
and is a goal of targeted therapy [7]. HER2 gene shows amplification in about 15-
20% of patients with breast cancers in Western countries. HER2-positive 
carcinomas were known to be very aggressive tumors with very poor prognosis 
until few years ago. New targeted therapies (trastuzumab) have been recently 
developed, which have improved the prognosis of these patients. It is very 
important to recognize these tumors to be treated properly [7], [8]. Beside HER2 
gene amplification and molecular subtypes, those prognostic factors such as 
patient’s age, the type of tumors, lymph node status, tumors size, histologic grade, 
estrogen receptor, progesterone receptor and proliferation index Ki67 also play an 
important role in the management and treatment of patients with breast cancer. 
1.2. Histopathological Characteristics 
1.2.1. Histologic Type 
Histopathological features have so far become important factors to diagnose 
cancers in general and breast cancers in particular [9]. Comprehensive knowledge of 
pathologists about normal histology of mammary glands is absolutely necessary for the 
accuracy of pathologic features evaluation. The alterations of mammary glands on X 
rays examination depend on genders, ages, menstrual cycles, pregnancy, breast-feeding 
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and menopause status. Thus, when deciding whether the mammogram result is normal 
or abnormal, it is necessary to consider all the above factors. 
Most breast tumors are carcinomas [10]. These malignant tumors are 
classified into in situ and invasive lesions. The most frequent breast cancers 
(occupied approximately 75%) belong to the group of invasive ductal carcinomas 
and the remaining ones have been divided into 17 distinct types. They include 
invasive lobular carcinomas, invasive papillary carcinomas, metaplastic carcinomas, 
tubular carcinomas and others [11]. 
According WHO histological classification of tumors of the breast 2012 [12], 
the histologic types is included: 
 Epithelial Tumors 
- Micro-invasive carcinoma 
- Invasive breast carcinoma: Invasive carcinoma of no special type (NST), 
Invasive lobular carcinoma, Tubular carcinoma, Cribriform carcinoma, Mucinous 
carcinoma, Carcinoma with medullary features, Carcinoma with apocrine 
differentiation, Carcinoma with signet-ring-cell differentiation, Invasive micro-
papillary carcinoma, Metaplastic carcinoma of no special type and Rare types 
- Epithelial- myoepithelial tumors 
- Precursor lesions 
- Intraductal proliferative lesions 
- Papillary lesions 
- Benign epithelial proliferations 
 Mesenchymal tumors 
 Fibroepithelial tumors 
 Tumors of the nipple 
 Malignant lymphoma 
 Metastatic tumors 
 Tumors of the male breast 
 Clinical patterns 
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1.2.2. Histologic grade [13] 
To determine the grade of breast cancer, different available "scoring 
systems" have been used. Nowadays, the Nottingham Histologic Score system (the 
Elston-Ellis modification of Scarff-Bloom-Richardson grading system) has a great 
tendency to be applied. According to this scoring system, there are three factors that 
the pathologists take into consideration, including the amount of gland formation, 
the nuclear features and the mitotic activity. Each of these features is scored from 1-
3, and then each score is added to give a final total score ranging from 3-9. 
The score is assessed following: 
 Glandular (acinar)/tubular differentiation 
- Score 1: >75% of tumor area forming glandular/tubular structures 
- Score 2: 10% to 75% of tumor area forming glandular/tubular structures 
- Score 3: <10% of tumor area forming glandular/tubular structures 
 Nuclear Pleomorphism 
- Score 1: Nuclei small with little increase in size in comparison with 
normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little 
variation in size 
- Score 2: Cells larger than normal with open vesicular nuclei, visible 
nucleoli, and moderate variability in both size and shape 
- Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting 
marked variation in size and shape, occasionally with very large and bizarre forms 
 Mitotic Count 
The mitotic count score criteria vary depending on the field diameter of the 
microscope used by the pathologist. The pathologist will count how many mitotic 
figures are seen in 10 high power fields. Using a high power field diameter of 0.50 
mm, the criteria are as follows: 
- Score 1: less than or equal to 7 mitoses per 10 high power fields 
- Score 2: 8-14 mitoses per 10 high power fields 
- Score 3: equal to or greater than 15 mitoses per 10 high power fields 
The final total score is used to determine the grade (Nottingham Histologic 
Score) in the following way: 
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1. Grade 1 tumors have a score of 3-5 
2. Grade 2 tumors have a score of 6-7 








Figure 1.3: Invasive Ductal Carcinoma [13] 
1.2.3. Tumour size 
Tumour size is an important prognostic factor of breast cancer. Tumour sizes 
are inversely proportional to survival rates and are directly proportional to distant 
recurrence rates [14]. An increase in tumour size will result in a decrease in survival 
rate regardless of lymph node status and as lympho nodes involvement increased, 
survival rates also drop without reference to tumor size. Tumor size and positive-
lympho node status have a linear relationship. Patients with a tumors size <2 cm 
have a higher 5-year survival rate than those with tumor size >5cm without 
consideration of lymph node status [15]. Besides, increased tumor size leads to 
rapid metastasis. Tumor size is also the strongest prognostic factor and has an 
important role in adjuvant treatment decisions when the lymph node involvement is 
absent [16]. 
The classification of primary tumor (T) size according WHO 2012 [12] 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
Tis (DCIS) Ductal carcinoma in situ 
Tis (LCIS) Lobular carcinoma in situ 
Tis (Paget) Paget disease of the nipple with not associated with invasive carcinoma 
and/or carcinoma in situ (DCIS and/or LCIS) in the underlying breast parachyma 
T1 Tumor 2 cm or less in greatest dimension 
T2 Tumor more than 2 cm but not more than 5 cm in greatest dimension 
T3 Tumor more than 5 cm in greatest dimension 
   
Histologic Grade I   Histologic Grade II    Histologic Grade III 
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T4 Tumor of any size with direct extension to the chest wall and/or to the 
skin (ulceration or skin nodules) 
1.2.4. Lymph node status 
Status of axillary lymph node metastasis is a significant prognostic factor. 
The number of positive axillary lymph nodes have a correlation with the risk for 
distant recurrence [17]. Nowadays, the number of metastatic nodes is used to access 
for stage of disease to decide the adjuvant therapy. In case of lymph node-negative 
patients and hormone receptor-positive tumors, endocrine therapy alone is often 
considered as the first choice of the treatment. 
1.2.5. Stage of disease 
Breast cancer is staged using the World Health Organization Classification of 
Tumours [12], which is based on: 
- The size of the breast tumor (T) and if it has grown into nearby areas 
- Whether the cancer has reached nearby lymph nodes (N) 
- Whether the cancer has metastasized (spread to other parts of the body) (M) 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage IIA 
T0 N1 M0 
T1 N1 M0 
T2 N0 M0 
Stage IIB 
T2 N1 M0 
T3 N0 M0 
Stage IIIA 
T0 N2 M0 
T1 N2 M0 
T2 N2 M0 
T3 N1 M0 
T3 N2 M0 
Stage IIIB 
T4 N0 M0 
T4 N1 M0 
T4 N2 M0 
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
Table 1.1: Stage grouping 
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1.3. Biomarker status in breast cancer 
1.3.1. Hormone receptors (Estrogen and Progesterone receptors) 
Estrogen and progesterone are steroid hormones which make a contribution 
to the development of normal breast. Both estrogen and progesterone are members 
of nuclear hormone receptor (HR) superfamily [18]. They can interact with 
hormone receptors in nuclear cell. Estrogen and progesterone regulate gene 
transcription through binding to DNA response factors directly or via other 
transcription elements and recruiting co-regulators. In addition, they can cross-talk 
with another signaling pathways through non-genomic mechanisms [18]. Estrogen 
and progesterone are main hormones involved in the regulation of tumor growth in 
breast cancer [19]. 
An experience consisting of 302 breast cancer patients conducted in Ivory 
Coast showed that ER and PR positivity was in 169 cases (56%) and 148 cases 
(50%), respectively [20]. The research implemented in 5,993 breast cancers by 
Nadji and colleagues, from USA, among 5,497 infiltrating breast carcinomas, 75% 
were ER-positive, 55% of tumors reacted positively to PR and 55% of cases 
expressed both ER and PR [21]. Expression of ER and PR is a very strongly and 
useful predictor. Thus, the determination of ER status has significant clinical values 
and is widely applied in routine histopathological diagnoses. The presence of ER is 
a good prognostic marker because it is an indicator of less aggressive tumors. The 
breast cancer patients with ER-positive have an overall longer survival and disease-
free time in comparison with ER-negative ones [22]. The evaluation of ER, PR aids 
in predicting the response to hormone therapy. Therefore, this is a routine test for 
breast cancer patients. 
1.3.2. Proliferation marker Ki-67 
Ki67 gene is located on the long arm of chromosome 10 (10q25) and encode 
Ki-67 protein in nuclear cell [23]. Ki67 protein expresses very low level in normal 
breast tissue (<3%) [24], [25]. 
In breast cancer, the evaluation of proliferation is one of the important factors 
for diagnosis, prognosis and treatment decisions. Many studies demonstrated that 
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Ki-67 is associated with the common histopathological parameters, as well as the 
biomarker. In a study with 12,155 breast cancer cases involved, De Azambuja and 
colleagues showed that the positive Ki-67 confers a higher risk of relapse and a 
lower survival rate. These authors have reported that high expression of Ki-67 is 
related with worse prognoses [26]. Bouzubar and co-workers have confirmed that 
there is a correlation between the high level of Ki-67 immunostaining and the 
early relapse of breast cancer after mastectomy [27]. In a research performed in 
Sweden the sample of which is collected from Vietnamese and Swedish breast 
carcinomas patients, Thang and colleagues have shown the correlation between 
Ki-67 and clinicopathological parameters. Using 15% as a cut- off value for Ki-
67, the rate of Ki-67>15% was 76% and 63% in Vietnamese and Swedish 
population, respectively [28]. Another study in Torino (Italy) with 1,688 luminal 
breast cancers involved, Bustreo et al. reported that the rate of Ki67≥14% is 
51.3% of all cases [29]. The research conducted by the Tumor Centre Regensburg 
(Bavaria, Germany) with the participation of 4,692 invasive breast cancer patients 
showed that the higher Ki-67 status was associated with higher grade, higher 
tumor stage and more aggressive tumor [30]. 
1.4. Human epidermal growth factor receptor 2 (HER2) 
1.4.1. HER2 protein and HER2 gene 
Human epidermal growth factor receptor 2 (HER2) is one of four members 
of the epidermal growth factor receptor (ErbB) family, encoded by the gene located 
on the long arm chromosome 17 (17q12). This is a tyrosine kinase transmembrane 
growth factor receptor involved in signal transduction pathways that regulate cell 
growth and differentiation. The ErbB/HER protein-tyrosine kinases consist of a 
growth-factor-binding extracellular domain, a single transmembrane part, an 
intracellular protein-tyrosine kinase catalytic domain and a tyrosine-containing 
cytoplasmic tail [7], [31]. 
Until now, many studies showed that HER2 has no identified ligand. 
Therefore, they believe that the activation have been occurring through 
heterodimerization with another HER family member, although HER2 homodimers 
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can also form when overexpressing. Heterodimers could make more powerful 
signals than homodimers. Heterodimers containing HER2 might have an extremely 
high ligand binding and signaling potency compared to hetero-and homodimers 
without HER2. Among all members of HER family, HER3 is the preferred 
dimerization partner of HER2. The combination HER2-HER3 is the most potent 
heterodimer in carcinoma cells, causing the most mitogenic index [32], [33]. 
Heterodimers of HER2-HER3 cause increased stability and prolonged activation, 
leading to enhanced downstream outcomes such as proliferation, migration, 
differentiation and survival [7], [33], [34], [35]. 
 
Figure 1.4: Signal Transduction by the HER Family [36] 
1.4.2. HER2 overexpression and HER2 gene amplification 
HER2 protein overexpression or HER2 gene amplification has an important 
role to play in breast carcinoma and highly correlated with cell proliferation, 
survival, differentiation, invasion, metastasis and bad prognosis [7], [31], [37], [38]. 
Approximately 15-20% of breast cancer patients in Western countries 
have HER2 gene amplification [37]. This rate is higher in Asian countries such 
as Malaysia (32.6%), ThaiLan (44.2%), HongKong (26.9%) than that in Western  
countries according to some published studies on women from the latter 
countries [39]. 
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No Name 





1 Pathmanathan [39] 68.9 31.1 South Vietnam 
2 Thang V.H [40] 59 41 North Vietnam 
3 Pathmanathan [39] 67.4 32.6 Malaysia 
4 Choi [41] 62.5 47.5 Korea 
6 Hadi [42] 81.4 18.6 USA 
7 Rasmussen [43] 76.9 23.1 Denmark 
8 Thang V.H [40] 86 14 Sweden 
9 ASCO-CAP 2013[37] 
 
15-20 Western 
Table 1.2: Prevalence of HER2 positivity in patients with breast cancer 
Overexpression of HER2 protein may occur in either the presence or absence 
of HER2 gene amplification. Many studies have showed that the correlation 
between HER2 and breast cancer outcome. The patients with HER2-positive tumors 
have a poorer prognosis than others with HER2-negative tumors [44], [45], [46], 
[47]. In 1987, Slamon and colleagues showed the correlation between HER2 status 
and the prediction of overall survival and time to relapse in node-positive patients 
[48]. Many studies have the similar result to Slamon’s study [35], [49], [50], [51]. 
Another publication in 2015 suggested that there was no association between HER2 
expression and age, histological type but a correlation with grade, size and nodal 
involvement [52]. In 2005, Ariga and co-workers found a correlation between 
HER2/neu amplification and tumor type, high histological grade, and high 
proliferative MIB-1 index whereas there was no correlation between the size of 
tumors and the age of patients with HER2 positive [53]. Shokouh and colleagues, in 
their study conducted in 566 breast cancers, have recently showed a significant 
correlation between the tumor grade and HER2 overexpression [52], [54]. A similar 
result was found in the study on women in Asian countries presented with breast 
cancer at higher histological grade [39], [55]. In addition, many studies showed that 
there was an inverse relation between HER2 expression and steroid hormone 
receptor status [53], [56], [57]. 
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The tumors with higher Ki-67 expression are also associated with a 
higher HER2 overexpression. High proliferation was correlated with poor 
prognostic factors such as high grade, negative estrogen receptor and HER2 
amplification [28], [52]. 
1.4.3. Testing for HER2 protein overexpression and HER2 gene amplification in 
breast cancer 
Nowadays, many methods for HER2 testing have been developed, however, 
about 20% of current HER2 testing is not correct [58]. Therefore, the American 
Society of Clinical Oncology (ASCO) and the College of American Pathologists 
(CAP) have recommended guidelines in HER2 testing to ensure accuracy [37]. The 
two methods currently approved for HER2 testing are immunohistochemistry (IHC) 
and in situ hybridization (ISH). Beside the standard fluorescence in situ hybridization 
(FISH), there is a growing number of new ISH techniques which are applied, such as 
chromogenic in situ hybridization (CISH), silver-enhanced in situ hybridization (SISH) 
and dual in situ hybridization (DISH). The IHC has been used to detect the HER2 
overexpression and the ISH identifying the HER2 gene amplification. The concordance 
between IHC and FISH assessing of HER2 protein overexpression and gene 
amplification ranged from 73% to 98% [59], [60]. Fluorescence in situ hybridization 
(FISH) is a powerful technique used in the detection of chromosomal abnormalities. 
Fluorescence labeled DNA probes complementary to regions of individual 
chromosomes is used in FISH. These labeled DNA segments were hybridized with the 
cytological targets in the sample. Until now, HER2 fluorescence in situ hybridization is 
a gold standard to detect HER2 gene amplification in breast cancer. Recent studies 
report a high concordance between protein overexpression in IHC and amplification by 
FISH or CISH [61]. A new ISH technique with a fully automated, called the Dual ISH, 
detecting HER2 gene amplification was approved by U.S. Food and Drug 
Administration (FDA) in June 2011. The Dual-ISH test detects both HER2 gene and 
chromosome 17 on a single slide by a light microscope. This new technique is 
increasingly applied at many laboratories. Mansfield has recent shown that the 
concordance between FISH and DISH is 92% [62]. 
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1.4.4. HER2 and targeting therapy 
HER2- positive carcinomas were known to be very aggressive tumours with very 
bad prognosis until few years ago. New target therapies (trastuzumab) have been 
recently developed, which have changed the prognosis of these patients. Therefore, it is 
very important to recognize these tumours to be treated properly. Targeted therapies for 
breast cancer are new therapies using substances or drugs which block the evolution of 
cancer. Those therapies interfere the function of specific molecules responsible for 
tumor cell proliferation and survival. Recently, trastuzumab has been approved for the 
treatment of HER2 adjuvant breast cancer. This is the humanized monoclonal antibody 
consisting of two antigen-specific sites that can bind to the extracellular domain of the 
HER2 receptor and that prevent the activation of its intracellular tyrosine kinase [63]. 
In 2007, Hudis et co-workers reported that trastuzumab improved overall survival in 
late-stage HER2-positive breast cancer from 20.3 to 25.1 months [36]. Using 
trastuzumab alone or in combination with chemotherapy was a significant regimen in 
neoadjuvant therapies of the breast cancer treatment. 
 
Figure 1.5: Interactions between Trastuzumab and Tumor Cells [64]. 
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1.5. Classification of molecular subtype breast cancer 
Many researches have shown that breast carcinoma includes many groups of 
molecules. The treatment and prognosis differ among the groups. There is a 
variation among the studies in the way how molecular subtypes breast cancer were 
classified, but basically it was based on the expression of biomarkers (HER2, ER, 
PR, Ki67) in IHC and the amplification of HER2 gene in ISH. There are five main 
subtypes, including luminal A, luminal B-HER2 negative with high Ki67, luminal 
B-HER2 positive, HER2 enrich and triple negative breast cancer (TNBC). Luminal 
A subtype is the best survival one while the triple negative breast cancer subtype 
has the poorest survival. The 13th St Gallen International Breast Cancer Conference 
added the Ki67 index to distinguish between luminal A and luminal B. Many 
authors have used the 14% such as optimal cut off point of Ki67 in their studies. 
Luminal A is characterized by positive hormone receptor, negative HER2 status and 
Ki67<14%. Luminal B also has HR+, HER2-, but Ki67≥14%. The subtype with 
HR+ and HER2+ is classified to luminal B-HER2 positive [65], [66], [67]. HER2 
enrich subtype has HR-negative and HER2-positive markers. The triple negative is 


















Sun [68] 24 22 17 18 19 China (2015) 
Park [69] 53.1 5.2 16.4 9.1 16.2 Korea (2011) 
De Macêdo 
Andrade [70] 
23.8 10 34.6 14.5 17.1 Brazil (2014) 
El Fatemi [71] 30.5 41.8 9.2 18.5 Morocco (2012) 
Kondov [72] 26.6 31.4 24.1 8.6 9.3 Macedonia (2018) 
Caldarella  [9] 34 25 11 11 19 Italy (2012) 
Chaeng [73] 36 19 17 28 Canada (2009) 
Table 1.3: Distribution of molecular subtypes 
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The study of Sadek and colleagues (2017) also demonstrated that the 
distribution of molecular subtypes differ considerably in race, risk factors, 
prognosis and response to treatment [74]. TNBCs account for 10–16% of all breast 
cancers [75]. The incidence of TNBC varied by region as well as ethnicity with the 
highest rates in African-Americans (23.7%), and lowest in Filipino patients (8.9%) 
[76]. Triple negative had more high grade cancer and mortality compared to HER2 
subtype for black populations. [74]. The relapse rate of triple negative is the highest 
among the others [77], [78], [79]. The HER2 subtype is an aggressive tumour with 
bad prognosis, only responding to trastuzumab-targeted therapy. HER2 subtype had 
more late cancer stage compared to luminal [74]. In the Asians, the HER2 subtype 
is dominant compared to luminal A subtype in Western countries [9], [80]. In the 
study conducted in Canada, Fallahpour and co-workers showed that luminal A 
cancers accounted for 59.0% of all breast cancers. This is higher than the proportion 
found in other Canadian studies, 41%–44% [66], [81], [82]. Many studies have 
shown the significant correlation between molecular subtypes and the prognostic 
factors [83], [84], [85]. 
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2. AIMS OF THE STUDY 
 
Breast cancer is the most commonly occurring cancer and the leading cause 
of cancer deaths in Vietnamese women. Nowadays, the effectiveness of treatment 
aids in improving breast cancer survival time and its prognosis. However, the vast 
majority of breast cancer cases are diagnosed in late stage of disease with large size 
of tumors and metastasis. In addition, some advanced techniques like fluorescence 
in situ hybridization, dual in situ hybridization techniques which evaluate the HER2 
gene amplification are still not widely applied. Therefore, many cases are not 
properly diagnosed, classified and treated. The use of targeting therapy 
(trastuzumab) for treatment of breast cancer is very limited.  
Many studies have shown that breast cancer includes many molecular 
subtypes which have different treatments and prognoses. Therefore, the classification 
always has an important role to play in the choice of treatment therapies and the 
evaluation of response to therapy. 
So, we conducted this study with the following aims: 
1. To identify HER2 status of breast carcinoma patients in Central Vietnam 
2. To determine the molecular subtypes of breast carcinoma.  
3. To assess the relationship between HER2, molecular subtypes of breast 
cancer and prognostic factors.  
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3. MATERIALS AND METHODS 
 
3.1. Study sites 
This was a descriptive cross-sectional study, conducted from November 2015 
to October 2018, at following settings: 
- Anatomical Pathology Institute of Sassari University Hospital 
- Anatomical Pathology Department of Hue University Hospital 
- Anatomical Pathology Department of Hue Central Hospital 
3.2. Samples collection 
- The study included 88 surgical samples from patients that were diagnosed 
such as breast carcinomas at Hue University Hospital and Hue Central Hospital, 
Hue city, Vietnam from 04/2016 to 04/2017 
- The samples from the breast carcinoma patients who received perioperative 
chemotherapy in the past were excluded. 
- Specimens were fixed with 10% neutral-buffered formalin within 30 
minutes after taking off from patient’s body. 
- All samples were re-examined histopathology to confirm the breast 
carcinoma at Anatomical Pathology Institute of Sassari University Hospital. 
3.3. Samples preparation 
3.3.1. Fixation of specimens 
- The 10% neutral-buffered formalin (equivalent to 4% formaldehyde 
solution) was used to fix the specimens. Fixative volume was 10- 20 times as much 
as specimen volume. The optimal time for fixation is in 24 - 48 hours. 
3.3.2. Processing of specimens 
Following fixation, tissue specimens were processed by protocol for the 
surgical specimens 
3.3.3. Embedding in paraffin wax 
Following processing, specimens were embedded in fresh paraffin wax at 55-
60°C, then, stored at room temperature. 
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3.3.4. Sectioning paraffin block 
Section thickness for hematoxylin and eosin staining is about 2-3µm. 
Section thickness is also about 2-3µm for immunohistochemistry and 4-5µm for 
fluorescence in situ hybridization.  
3.4. Hematoxylin and Eosin (H&E) staining 
The slides containing paraffin sections were placed in a slide holder 
(glass or metal). The implementation of Hematoxylin and Eosin (H&E) 
stainstrictly followed the protocol which accompanied the staining machine. 
After then, the slides were coverslipped with Permount (xylene based). 
3.5. Immunohistochemical staining (IHC) for Her2-protein 
The HER2 protein was identified by immunohistochemistry by using 
PATHWAY anti-HER-2/neu(4B5) Rabbit Monoclonal Primary Antibody 5ml 
(~6µg/ml) by Ventana Benchmark Ultra automatic staining system [86]. 
3.5.1. Principles 
PATHWAY HER2 (4B5) is a rabbit monoclonal antibody binding to HER2 
in paraffin embedded tissue sections. The focalization of the specific antibody could 
be implemented by ultraView. The ultraView Universal DAB Detection Kit detects 
specific mouse and rabbit primary antibodies bound to an antigen in paraffin-
embedded tissue sections. The specific antibody is located by a cocktail of enzyme 
labeled secondary antibodies (HRP Multimer). The complex is then visualized with 
hydrogen peroxide substrate and 3, 3’diaminobenzidine tetrahydrochloride (DAB) 
chromogen, which produces a brown precipitate that is readily observed by light 
microscopy [87]. Every step requires accurate time and temperature. The reaction, 
at the end of every incubation step, is terminated by using the Ventana automated 
slide stainer which might aid in the sections washing to remove unbound material. 
This procedure could also be advantageous to the enhancement of desired reaction 
in following steps. In addition, the application of Lipid Coverslip™ could limit the 
reagents which are in water-based specimens to evaporate. 
3.5.2. Step by Step Procedure 
We applied the procedures for staining on the Ventana automated slide stainer 
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Procedure BenchMark ULTRA 
Deparaffinization Selected 
Cell Conditioning (Antigen Unmasking) Cell Conditioning 1, Mild 
Enzyme (Protease) None required 
Antibody (Primary) Approximately 16 minutes, 37°C 
Detection Kit (UltraView Universal DAB 
Detection Kit) 
Automated 
Counterstain (Hematoxylin) Hematoxylin II, 4minutes 
Post Counterstain Bluing, 4 minutes 
Table 3.1: Recommended Staining Protocols for PATHWAY                                       
anti-HER-2/neu (4B5) with ultraView Universal DAB Detection Kit [86]. 
The Ventana Medical Systems, Inc. UltraView Universal DAB Detection Kit 
is an indirect, biotin-free system for detecting mouse IgG, mouse IgM and rabbit 
primary antibodies. The kit is expected to identify targets by immunohistochemistry 
in section of formalin-fixed, paraffin-embedded and frozen tissue that are stained on 
the BenchMark Ultra systems [88]. 
- Apply slide bar code label which corresponds to the antibody protocol 
be performed. 
- Load the primary antibody, appropriate detection kit dispensers, and 
required accessory reagents onto the reagent tray and put them on the automated 
slide stainer. Check bulk fluids and waste. 
- Load the slides into the automated slide stainer. 
- Start the staining runs. 
- After finishing the run, remove the slides from the automated slide stainer. 
- Using a mild dishwashing detergent wash the slide to remove the coverslip 
solution, then dehydrate, clear, and coverslip with permanent mounting media in the 
usual manner. 
3.5.3. Scoring Conventions for the Interpretation of PATHWAY HER2 (4B5) 
We scored IHC results based on manufacturer's instruction, Interpretation 
Guide for VENTANA anti-HER2/neu (4B5) and Recommendation for HER2 
testing of ASCO- CAP 2013. 
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Figure 3.1: Evaluation of human epidermal growth factor receptor 2 (HER2) 









Figure 3.2: IHC Test Measures HER2 Protein Overexpression [86] 
Nguyen Phuong Thao Tien - HER2 status and molecular subtypes of breast cancer in Central Vietnam 
Ph.D thesis in Clinical Biochemistry and Clinical Proteomics of 
Ph.D School in Life Sciences and Biotechnologies - University of Sassari 
 
23 
    
3.6. Immunohistochemical staining (IHC) for ER, PR, Ki-67 and E-cadherin 
We have performed Estrogen receptor (ER), Progesterone receptor (PR), Ki-
67, E-cadherin assay by using respectively VENTANA anti-Estrogen Receptor 
(SP1) Rabbit Monoclonal Primary Antibody, anti-Progesterone Receptor (1E2) 
Rabbit Monoclonal Primary Antibody, anti-Ki-67 (30-9) Rabbit Monoclonal 
Primary Antibody, anti-E-cadherin (36) Mouse Monoclonal Primary Antibody with 
Ventana Benchmark Ultra automatic staining system. The process was conducted 
similar to IHC staining for HER2 protein by Ventana Benchmark Ultra automatic 
staining system. 
We selected a Ki67 index of 14% as the cut point for evaluation, the cells 
stained ≥ 14% were considered as high. ER and PR are scored using ≥1% of tumor 
staining as the positive. 
The results were confirmed by experts in Anatomical Pathological Institute 
of Sassari University Hospital. 
3.7. Fluorescence in situ hybridization (FISH) for HER2 gene [89] 
FISH for HER2 gene amplification 
At the Institute of Pathological Anatomy of Sassari, the samples have been 
analyzed for HER2 gene amplification with Fluorescence In Situ Hybridization (FISH) 
method. The currently recommended methodology for the identification of HER2 gene 
amplification is the FISH analysis using PathVysion HER2 DNA probe kit (Abbott 
Molecular Inc) that has been optimized only for identifying and quantifying 
amplification of the HER-2 gene. The kit is intended for in vitro diagnostic (IVD) [89], 
[90], [91], [92], [93], [94], [95]. Formalin-fixed and paraffin-embedded 4µm sections, 
after deparaffinization with Hemo-de reagent, have been immersed in 0.2N HCl for 20 
minutes; after, they have been washed in purified water first and wash buffer then. The 
pretreatment stage has been performed at 80 ± 1°C for 30 minutes. After sequential 
washes, the slides are subjected to a Protease Treatment at 37 ± 1°C for 10 to 60 
minutes. In general, the time is around 30 minutes but depends on the size of the slide. 
For the slide of 3µ, the time is 30 minutes. The 3µ is the best size of the slide that 
should be analyzed by FISH assay. After fixing the slides with formalin for 10 minutes 
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at room temperature and after the dehydration, the DNA has been denatured at 72°C 
for 5 minutes and then hybridized at 37°C overnight into the Hy-Brite, after the 
addition of the PathVysion HER2 DNA probe. Following the hybridization, the slides 
are washed with the wash buffer and colored with 4’, 6-diamidino-2-phenylindole 
(DAPI) solution and cover-slipped. The hybridized slides are stored at -20°C and 
protected from light until their reading on the microscope. The evaluation of HER-2 
amplification gene has been analyzed by direct detection using fluorescence 
microscope by Olympus BX41. The first step has been the localization of the tumor 
area using the 4X and 10X objectives, avoiding the areas of necrosis and where the 
nuclear borders are ambiguous (tumor cells as identified by H & E stain). 
After locating the area and positioning the immersion oil, using the 100X 
objective, the slides have been evaluated using the prescribed filters to analyze the 
quality of HER2 signals and quality of tissue morphology. It was used 4 different filters 
to analyze the slides: first of all, DAPI filter to distinguish the nuclear boundaries and 
the integrity of the nuclei and then a triple filter (DAPI/red/green) to distinguish the 
nuclear boundaries (DAPI filter) and the hybridization of the probe, with red and green 
signals (RED/GREEN filter); for each nucleus, has count the number of LSI (Locus 
specific identifier) HER-2/neu signals and the number of CEP 17 signals. 
LSI HER-2 to CEP 17 Ratio Determination 
After scanning several areas of tumor cells to account for possible 
heterogeneity, it was been selected an area of good nuclei distribution. Using 100X 
objective, the analysis has been started in the upper left quadrant of the selected area 
and, scanning from left to right, has been count the number of signals within the 
nuclear boundary of each evaluable interphase cell according to the worldwide 
guidelines. The recommended method for LSI HER-2/neu to CEP 17 ratio 
determination is by dividing the total number of LSI HER-2/neu signals by the total 
number of CEP 17 signals in counting the same 20 nuclei. For each nucleus, must 
be count the number of LSI HER-2/neu signals and the number of CEP 17 signals. 
To calculate the final result, has been used the following ratio: total LSI HER-2/neu 
signals/total CEP 17 signals. 
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We based on the ASCO/CAP Guideline Update 2013 for recommendations 
for human epidermal growth factor receptor 2 testing in breast cancer to analyse the 
final results [37]. If the LSI HER-2/neu to CEP17 ratio is ≥2, HER-2/neu gene 
amplification was observed. In case of the ratio is <2, should be count the average 
HER2 copy number. If the average HER2 copy number ≥6.0 signals/cell, the HER-
2/neu gene amplification was reported. If the average HER2 copy number <4.0 
signals/cell, HER-2/neu gene amplification was not observed. In case of the 
borderline (the average HER2 copy number ≥4.0 signals/cell and <6.0 signals/cell), 
should be count an additional 20 nuclei and recalculate the ratio based on the total 
of 40 nuclei. If still in doubt, the assay was repeated with a fresh specimen slide. 
 
 HER2 Not Amplified HER2 Amplified 
Figure 3.3: HER2 gene amplification by FISH 
 
Figure 3.4: Evaluation HER2 gene amplification by In Situ Hybridization (ISH) [37] 
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3.8. Dual color in situ hybridization (DISH) for HER2 gene [96] 
DISH for HER2 gene amplification 
The DISH was performed at Anatomical Pathology Department of Hue 
University Hospital, Vietnam for 52 selected cases, included 27 negative HER2 
cases, 8 equivocal HER2 cases and 17 positive HER2 cases in IHC. 
The HER2 gene amplification was defined by Dual In situ Hybridization using 
the INFORM HER2 Dual In Situ Hybridization DNA probe cocktail assay by Ventana 
Medical Systems. This technique identifies HER2 gene status by detecting the HER2 
copies via silver in situ hybridization (SISH) and the Chromosome 17 (Chr17) copies 
via chromogenic red in situ hybridization (Red ISH) on a single slide. 
Routinely processed, formalin-fixed and paraffin-embedded tissues were 
applied to this technique. The section should be cut approximately 3-4µm of 
thickness. Then, we have performed DISH assay following the protocol setting on 
Ventana BenchMark Series automated slide stainers 
Procedure BenchMark 
Deparaffinization Selected 
Extended Depar Not Selected 
Cell Conditioning Selected 
Cell Conditioning CC2 
Mild CC2 - 8 min 
Standard CC2 - 12 min 
Extended CC2 - 8 min 
ISH-Protease 3 16 min 
Denaturation 20 min 
Hybridization 6 hours 
Stringency wash 72°C 
SISH Multimer 16 min 
Silver Chromogen 4 min 
Red ISH Multimer 24 min 
Red Chromogen 8 min 
Counterstain Hematoxylin II, 8minutes 
Post Counterstain Bluing Reagent, 4 minutes 
Table 3.2: Recommended Staining Protocol for INFORM HER2 Dual ISH DNA 
Probe Cocktail on Ventana BenchMark Series automated slide stainers 
Nguyen Phuong Thao Tien - HER2 status and molecular subtypes of breast cancer in Central Vietnam 
Ph.D thesis in Clinical Biochemistry and Clinical Proteomics of 
Ph.D School in Life Sciences and Biotechnologies - University of Sassari 
 
27 
    
We have applied the slide bar code label that corresponds to the probe protocol 
to be performed. After then loading the INFORM HER2 Dual ISH DNA Probe 
Cocktail, reagents from UltraView Red ISH DIG and UltraView SISH DNP 
Detection Kits, and requiring accessory reagents into the reagent tray(s). Reagent 
tray(s) were placed on automated slide stainer. Loading slides into the automated 
slide stainer and starting the staining run. At the run has finished, remove slides from 
the automated slide stainer and start proceeding with dehydration procedure. 
Removing liquid coverslip solution and washing the slides in 2 sequential solutions of 
a mild dishwashing detergent (do not use detergent designed for automatic 
dishwashers). After then, the slides were rinsed well with distilled water, about 1 
minute. Shake off excess water. Then put the slides in an oven (45-60°C) to dry or air 
dry at ambient temperature. In an oven, drying times range from 10 minutes to one 
hour until completely dry. After then, the slides were cover-slipped and transferred 
into xylene bath for approximately 30 seconds. Then, place coverslip on slide. 
 
Figure 3.5: HER2 gene amplification by Dual ISH (DISH) 
Interpret the result of DISH: 
Using objectives as high as 40X to 60X of light microscopy to enumerate the 
black signals of HER2 gene amplification and the red signals of Chromosome 17 
for all 20 nuclei in the invasive breast carcinoma, basing on the guideline of 
Ventana. To calculate the final result, has been used the following ratio: Total 
HER2/neu signals/ Total CEP 17 signals. 
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After then, we have analysed final results basing on the ASCO/CAP 
Guideline Update 2013 for the recommendations for human epidermal growth 
factor receptor 2 testing in breast cancer [37]. This evaluated way is absolutely 
similar to that in FISH technique. 
If the LSI HER-2/neu to CEP 17 ratio is ≥ 2, HER-2/neu gene amplification 
was observed. In case of the ratio is < 2, should be count the average HER2 copy 
number. If the average HER2 copy number ≥ 6.0 signals/cell, the HER-2/neu gene 
amplification was reported. If the average HER2 copy number <4.0 signals/cell, 
HER-2/neu gene amplification was not observed. In case of the borderline (the 
average HER2 copy number ≥ 4.0 signals/cell and < 6.0 signals/cell), should be 
count an additional 20 nuclei and recalculate the ratio based on the total of 40 
nuclei. If still in doubt, the assay was repeated with a fresh specimen slide. 
3.9. Study design 
All specimens were re-examined on Hematoxylin-Eosin staining to confirm, 
at Institute of Pathological Anatomy of Sassari University Hospital, the 
histopathological diagnosis of the breast carcinoma. Classification of tumors based 
on WHO histological classification of tumors of the breast, TNM classification of 
carcinomas of the breast 2012 and the Nottingham Histologic Score system (the 
Elston-Ellis modification of Scarff-Bloom-Richardson grading system). The IHC 
was performed on all formalin-fixed paraffin embedded tissue sections of patients. 
FISH technique was performed on all HER2 equivocal (2+) cases in IHC. The 
Dual-ISH assay was applied to 52 selected cases. 
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Figure 3.6: Scheme of study design 
3.10. Statistical analysis 
The data has been collected and stored using Excel, then has been analyzed 
with SPSS 16.0 
Samples 
Hematoxylin - Eosin 







HER2 gene amplification 
Malignant Tumor 









ER, PR, Ki67 
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4. RESULTS 
 
4.1. Clinicopathological characteristics of specimens 
We collected 88 specimens of invasive breast carcinomas in women. The 
clinicopathological characteristics of those specimens include age, tumour size, 
histological type, histological grade, lymph node involvement and stage of 
disease which are shown in the table below: 
Parameters Number (%) 
Age 
Range 29-91 
Median ± standard deviation (X ± SD) 52.5 ± 12.8 
< 50 29 (33) 
≥50 - <70 49 (55.7) 
≥ 70 10 (11.4) 
Tumor size 
≤2 24 (27.3) 
>2- ≤5cm 48 (54.5) 
>5cm 16 (18.2) 
Histological type 
Ductal 82 (93.2) 
Others 6 (6.8) 
Histological grade 
I 9 (10.2 ) 
II 40 ( 45.5) 
III 39 (44.3 ) 
Lymph node status 
           No metastasis 38 (43.2) 
Metastasis 48 (54.5) 
Unknown 2 (2.3) 
Stage of disease  
I 13 (14.8) 
II 47 (53.4) 
III 26 (29.5) 
Unknown 2 (2.3) 
Table 4.1: Clinicopathological characteristic of specimens 
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In our study, the median age was around 52 years (range between 29 and 
31). The group of women aged 50-79 occupied the highest proportion, at 55.7%. 
The most common tumor size was 2 – 5cm, with a percentage of 54.5%. The 
invasive ductal carcinoma accounted for the vast majority of samples, at about 
93.2%. The classification of histologic grade was applied based on Nottingham 
Histologic Score system (the Elston-Ellis modification of Scarff-Bloom-
Richardson grading system). The tumors which were of histologic grade II and 
III was found in 89.8% of cases while the figure for grade I is lower, at 10.2%. 
The cases which had lymph node metastasis accounted for 54.5%, higher than 
those with no metastasis. The stage of diseases was assessed based on TNM 
classification of breast carcinoma 2012. While the highest rate is stage II, at 




Chart 4.1: Relationship between tumour size and histologic grade 
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p<0.05 
Chart 4.2: Relationship between tumour size and lymph node status 
The chart 4.1 and chart 4.2 showed that there was a significant difference 
between the tumour size and histological grade as well as metastasis, with p<0.05. 
Most of the tumours with more than 5cm in size had grade III (68.8%) and the 
figure for tumours with metastasis was 75%. 
 
p<0.001 
Chart 4.3: Relationship between the tumour size and Ki67  
Our data demonstrated that the vast majority of tumors larger than 5cm in 
size expressed a high level of Ki67 (93.7%) compared to that of tumors smaller than 
2cm in size (66.7%). The difference is statistical significance.  
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Figure 4.1: Code 6497. Invasive Ductal Carcinoma 
4.2. Human epidermal growth factor receptor 2 (HER2) status 
4.2.1. HER2 protein overexpression in immunohistochemistry 
HER2 protein overexpression 
Total 
Number Percentage (%) 
Negative 
0 50 56.8 
60.2 
1+ 3 3.4 
Equivocal 2+ 8 9.1 
Positive 3+ 27 30.7 
Total 88 100% 
Table 4.2: HER2 protein overexpression in immunohistochemistry 
We performed HER2 immunohistochemical staining in 88 samples. The 
results of HER2 protein over-expression were interpreted as 0 and 1+ (negative); 2+ 
(equivocal) and 3+ (positive) score according ASCO-CAP guideline 2013. We had 
27 breast cancer samples (30.7%) which were defined as positive for HER2 protein 
over-expression, 8 cases with 2+ score (9.1%) as equivocal and 53 negative cases, 
accounting for 60.2%. 
    
 Grade III (x10) Grade III (x40) 
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Figure 4.3: Code 2813. HER2 protein over-expression 3+ score (positive) 
4.2.2. HER2 gene amplification by Fluorescence In Situ Hybridization 
We used FISH assay to identify HER2 gene amplification with 8 cases 
having (2+) score in IHC. The results were presented in the table below: 
HER2 gene amplification 
Total 
Number Percentage (%) 
Negative 6 75.0 
Equivocal 0 0 
Positive 2 25.0 
Total 8 100% 
Table 4.3: HER2 gene amplification by FISH 
  




    HER2 (3+) x 10     HER2 (3+) x 40  
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Figure 4.4: Code 6497. HER2 gene amplification by FISH 
Based on the IHC and FISH results for HER2, HER2 positivity was 
defined as either an HER2 (3+) in IHC or an amplification of the HER2 gene in 
FISH. Therefore, we had 29 cases with HER2-positive (approximately 32.9%) 
and those with negative results were 59 cases, collectively accounting for about 
67.1% in total. 
HER2 status Number Percentage (%) 
     Negative 59 67.1 
Positive 
3+/ IHC 27 
29 32.9 
Amplification/FISH 2 
Total 88 100 
Table 4.4: HER2 status on breast cancer 
4.3. Biomarker status 
Parameters Number (%) 
ER status 
Negative 39 ( 44.3) 
Positive 49 (55.7) 
PR status 
Negative 52 ( 59.1) 
Positive 36 (40.9) 
Ki67 
< 14% 16 (18.2) 
≥ 14% 72 (81.8) 
Table 4.5: Biomarker status of breast cancer 
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We obtained IHC results of ER, PR and Ki-67 in 88 cases. The ER positive 
was responsible for approximately 55.7% of cases, followed by the ER negative, at 
44.3%. The figure for PR positive and negative was 40.9% and 59.1%, respectively. 
For the proliferation index Ki67, 14% was chosen as an optimal cut off for the 
division of 2 groups of Ki67 in this study. The proportion of group with high Ki67 






















Figure 4.6: Code 6497. Proliferation index Ki67 
 
 ER (+)90% x10 ER (+)90% x20 
 
 
 Ki67 (+)60% x10 Ki67 (+)60% x20 
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4.4. Molecular Subtypes Breast Cancer 
Molecular subtypes of breast carcinoma were classified based on the 
biomarkers status such as ER, PR, Ki67, HER2 in accordance with the 13th Saint 
Gallen conference 2013 and using 14% as an optimal cut off point of Ki67. There 
were five groups including luminal A, luminal B-HER2 negative, luminal B-HER2 
positive, HER2 enrich and triple negative breast cancer. The luminal B was the 
most frequent in this study, at 37.5% while the uncommon belonged to luminal A, 
at 18.2%. The HER2 enrich and triple negative breast cancer were 22.7% and 
21.6%, respectively (chart 4.4). 
 
 
Chart 4.4: Distribution of molecular subtype of breast cancer 
4.5. Relationship between HER2 and prognostic factors 
4.5.1. Relationship between HER2 and clinicopathological characteristics 
A significant difference between HER2 status breast cancer and histological 
grade was found with p< 0.001. We also observed the differences between the 
HER2 status and tumor size, stage of disease, lymph node status, however, not 
reaching statistical significance. 
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< 50 17 (28.8) 12 (41.8) 
≥50 - <70 34 (57.6) 15 (51.7) 




≤2 cm 19 (32.2) 5 (17.2) 
>2- ≤5cm 33 (55.9) 15 (51.7) 
>5cm 7 (11.9) 9 (31.1) 




I 12 (21.1) 1 (3.4) 
II 31 (54.4) 16(55.2) 




Ductal 53 (89.8) 29 (100.0) 





I 9 (15.3) 0 (0.0) 
II 34 (57.6) 6 (20.7) 
III 16 (27.1) 23 (79.3) 
Lymph node status 
 
p= 0.08 
No metastasis 29 (50.9) 9 (31.1) 
Metastasis 28 (49.1) 20 (68.9) 
Table 4.6: Relationship between HER2 and clinicopathological characteristics 
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4.5.2. Relationship between HER2 and biomarkers 
There was a significant difference between HER2 status breast cancer and 
ER status (p< 0.001). The majority of samples in HER2-positive group (69%) had a 
negative ER status. A statistically significant difference was seen between HER2 
status and proliferation index Ki67 (p<0.005). All the samples of positive HER2 












Negative 19 (32.8) 20 (69.0) 




Negative 32 (54.2) 20 (69.0) 




< 14 16 (27.1) 0 (0.0) 
≥ 14 43 (72.9) 29 (100.0) 
Table 4.7: Relationship between HER2 and biomarkers 
4.6. Relationship between molecular subtypes and prognostic factors 
In our study, we have found statistically significant differences between 
molecular subtype and histological type, histological grade, biomarkers (ER, PR, 
Ki67, HER2) with p <0.001. There was also a significant difference between 
molecular subtype and stage of disease with p<0.05. Most of the luminal A cases 
had stage I (43.7%), no metastasis (62%) and low Ki67 (100%). In contrast, the 
TNBCs and also HER2 enrich subtype were often in grade III, higher metastasis 
and higher Ki67. 
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Luminal A Luminal B HER2enrich TNBC 
Number (%) 










<50 4 (25) 11 (33.4) 7 (35%) 7 (36.8) 




≤2 8 (50%) 8 (24.2) 4 (20) 4 (21.1) 
>2- ≤5cm 7 (43.8%) 17 (51.6) 12 (60) 12 (63.3) 
>5cm 1 (6,2%) 8 (24.2) 4 (20) 3 (15.6) 
Stage of disease 
 
p= 0.029 
I 7 (43.7) 3 (9.1) 1 (5) 2 (10.6) 
II 6 (37.5) 19 (57.6) 12 (60) 10 (52.6) 
III 1 (6.3%) 11 (33.3) 7 (35) 7 (36.8) 




Ductal 11 (68.8) 32 (66.9) 20 (100) 19 (100) 




I 6 (37.5) 2 (6.1) 0 (0) 1 (5.3) 
II 10 (62.5) 19 (57.6) 4 (20) 7 (36.8) 
III 0 (0) 12 (36.4) 16 (80) 11 (57.9) 
Lymph node status 
p= 0.141 
 
No metastasis 10 (62.5) 12 (36.4) 9 (45) 7 (36.8) 
Metastasis 4 (25) 21 (65.6) 11 (55) 12 (63.2) 




<14% 16 (100) 0 (0) 0 (0) 0 (0) 
≥ 14% 0 (0) 33 (100) 20 (100) 19 (100) 
Table 4.8: Relationship between molecular subtype and prognostic factors 
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Chart 4.5: Distribution of molecular subtype breast cancer by age 
The chart 4.5 showed that the luminal A subtype was common in women 
aged 55-60 years. The prevalence of luminal B-HER2 negative and HER2 enrich 
subtype reached its peak at the age of 50-55. Interestingly, triple negative subtypes 
were common in all three age groups: from 35 to 40, 50-55 and over 70 years old. 
Luminal B-HER2 positive was extremely prevalent at 2 age groups: very young 
women aged between 35 and 40 like triple negative subtype and middle aged 50-55, 
like other subtypes. 
 
Chart 4.6: Relationship between molecular subtypes and tumour size 
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The  chart above demonstrated that the majority of luminal A cases were the 
small-sized tumours (≤ 2cm), accounting for 50%. The tumors with a large size 
(≥5cm) just occupied 6.2% of luminal A cases. The proportion of tumours ≤ 2cm in 
size accounted for 24.2%, 20% and 21.1% of the total in the group of luminal B, 
HER2 enrich and triple negative subtype, respectively. Most of the tumours in  
luminal B, HER2 enrich and triple negative subtype group were larger than 2cm. 
4.7. Concordance between IHC and DISH results 
We performed DISH technique to identify HER2 gene amplification for 52 
samples selected from our original ones. Those samples underwent IHC, which 
included 26 samples in 0 score, 1 sample in (1+) score, 8 samples in (2+) score and 
17 samples in (3+) score. The results of DISH are shown in the table 4.9. 
HER2 gene amplification 
Total 
Number Percentage (%) 
Negative 33 63.5 
Equivocal 0 0 
Amplified 19 36.5 
Total 52 100% 
Table 4.9: HER2 gene amplification by DISH 
 
Figure 4.7: Code 6497. HER2 gene amplification by DISH 
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Comparing the results of DISH to that of IHC assay, we have found the 
concordance between two techniques: 
IHC Score 
Dual-ISH Concordance rate 
(%) Amplified Not Amplified 
0 0 26 100 
1+ 0 1 100 
2+ 2 6 25 
3+ 17 0 100 
Table 4.10: Concordance between IHC and DISH 
In this study, all of the samples which had negative HER2 protein 
overexpression in IHC (score 0 and 1+) were also not amplified of HER2 gene in 
DISH. The concordance rate between IHC and DISH was 100% regardless of the 
positivity of HER2 status. Table 4.10 showed that all cases of HER2-positive in 
IHC had an amplification of gene in DISH. However, for 8 equivocal cases in IHC, 
we had 2 HER2 gene amplified cases and 6 cases without amplification. 
The concordance rate between IHC and DISH assay were 100% and 25% 
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5. DISCUSSION 
 
5.1. Clinicopathological characteristic of specimens 
The results from our study have shown that the median age at diagnosis of 
breast cancer was 52.5. The youngest patient was 29 years old and the oldest 
patient was 91 years old. The median age in our results is similar to that in other 
reports of many Asian countries, such as China and Japan (around 53.9) [97], 
Korea (around 51) [98] but is lower than that of Western countries (Sweden, 
Italia), namely 63 years old [97], [99]. In a study conducted by Onitilo et al. in the 
USA, the mean age is higher, at 62.7 years [100]. The 50- to 70-year–old group of 
our data accounted for the highest proportion, at 55.7%. Another study in Italy, 
36% of patients diagnosed with breast cancer were in the group of age between 50 
to 69 years old. The patients with over 70 years old occupied 21% [101]. 
The histological type of this study is shown to be similar to that of many 
other studies with 93.2% invasive ductal carcinoma [84], [97], [100]. Tumour size 
from 2 to 5 cm is the most prevalent, which is different from studies of Onitilo 
(2009) and Colleoni (2011). Their studies reported that the tumours less than 2cm in 
size occupied the highest proportion [100], [102]. Most of the tumours in our 
samples were in grade II and grade III, collectively accounting for 89.8% while the 
early grade (grade I) was just a minority 10.2%. This is untrue for the study of  
Onitilo (from USA) as well as the study of Colleoni (from Italy), which showed a 
higher percentage of grade I (about 23%) compared to  our study [100], [102]. 
These dissimilarities between our study and others may occur as a result of 
the differences in races, lifestyles, living environments and age at menarche, 
menopause status, number of previous pregnancies [103], [104] or expression of 
late diagnosis. 
Our study have shown that the stage II and stage III were the majority with a 
proportion of 82.9 % whereas stage I occupied a lower percentage. This data is 
similar to study of Vu Hong, which was also carried out in Vietnamese women with 
70% for stage II and 19% for stage III [105]. However, those figures followed an 
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opposite pattern compared to a study of Leong et al., from Sweden, with 56% of the 
invasive cancers belonging to stage I, 37% for stage II, 5 % for stage III, and 2% for 
stage IV [97]. The study of Onitilo and colleagues, from USA, also showed that the 
most common breast cancer was classified as stage I (56.4%) while stage II and III 
occupied 36% and 7.7%, respectively [100]. 
Similar to staging, most of our samples showed nodal metastasis, at 54.5%, 
which is higher than in some studies of foreign authors such as Carey (USA) at 
39%, Spitale (Switzerland), at 37.1% and Onitilo (USA), at 33.5% [5], [79], [100]. 
In our study, statistically significant differences were found between the size of the 
tumour and histological grade as well as the tumour size and metastasis with 
p<0.05. The rate of grade III was approximately 68.8% of tumours more than 5cm 
in size compared to 20.8% of tumours less than 2cm in size (chart 4.1). In addition, 
most of cases with a large tumour in size (≥5cm) had metastasis (chart 4.2). 
 The differences about clinicopathological characteristic between our result 
and other studies may be due to the varying characteristics among populations and 
the late-stage diagnosis. It is mainly because breast cancer screening programs have 
not widely applied in general population. Information about screening processes and 
the integration of screening services into other areas of the health system are not 
sufficiently provided. Therefore, many breast carcinoma patients present to hospital 
with large tumour size, late stage of disease, high grade and metastasis. 
5.2. HER2 protein overexpression and HER2 gene amplification 
Immunohistochemistry and fluorescence in situ hybridization have been 
applied into HER2 testing. Although both methods of IHC and FISH have been 
approved by FDA, FISH assay proves to have higher sensitivity and specificity. 
However, the cost of FISH technique is much higher, so FISH should be used only 
in case of HER2 (2+) in IHC and when trastuzumab monotherapy is indicated. Until 
now, FISH technique is generally known as the gold standard. 
We performed IHC to detect HER2 protein overexpression by using 
PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody, on 
Ventana Benchmark Ultra automatic staining system at the Institute of Pathological 
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Anatomy of Sassari. The results of the HER2 receptor status assessment using the 
IHC method are shown in table 4.2. We had 30.7% for score (3+) and 9.1% for 
score (2+). In case of HER2 (2+) in IHC, we performed the FISH technique to 
identify the gene amplification. We had 25% of cases with amplification and 75% 
of cases no amplification by FISH. Our result showed that, the prevalence rate of 
HER2 positive was 32.9% in total (table 4.4). 
Regarding the results of HER2 gene amplification, when making a 
comparison between our study and other two previous studies on Vietnamese 
women, one of which was conducted in Vietnam and the remaining was in Sweden; 
it is seen that there is a similarity with a high incidence of HER2 positive [39], [40]. 
The comparison between HER2 gene amplification results in this study and 
other studies are shown in chart 5.1 
 
Chart 5.1: Comparison the rate of HER2 gene amplification 
According ASCO-CAP 2013, the incidence rates of HER2-positive breast 
cancers account for approximately 15% -20% of total in Western countries [37]. 
Interestingly, the result of our study was different from the previous one 
conducted on Western women. The rate of HER2-positive breast carcinoma 
diagnosed in Vietnamese women is generally higher than in published studies on 
women from Western countries, such as study of Clavarezza in Italy [106], Bruun 
Rasmussen in Denmark [43], Choritz in Germany [107], and Thang in Sweden 
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[40]. Another study of Yaziji and co-workers performed in USA demonstrated a 
much lower rate of HER2 positive than my result did in Vietnam [42]. However, 
many studies in Asian women observed a similar rate of HER2-positive to our 
data [39]. Our study is also similar to the study of Pathmanathan which was 
conducted in Southern Vietnam [39]. Especially, the study of Thang which 
assessed HER2 status in Northern Vietnamese women and whose techniques was 
performed in Sweden showed that the rate of HER2 positive is 41%, a little bit 
higher than in our research [40]. 
Although the results of studies are inconsistent between authors, many recent 
studies have shown that the women population from Asian countries, including 
Vietnam have a substantially higher incidence of HER2-positive breast cancers 
compared to Western ones [39], [108]. These differences may be due to the 
variations in population characteristics such as biological tumours, ethnicity, 
geography and environment [39], [40], [109]. However, according to ASCO-CAP 
2013, the differences in the rate of HER2 receptor expression are mainly  attributed 
to the distinctive biology of the breast cancer patient population [37].  
5.3. The classification molecular subtypes breast carcinoma 
5.3.1. Biomarkers status 
Hormone receptor and proliferation index were analysed by 
immunohistochemistry (IHC) using an automated slide stainer (Bench Mark Ultra, 
Ventana). Of 88 samples, we have 55.7% positive for ER, 40.9% positive for PR 
and 81.8% for Ki67≥14% (table 4.5). Our result corresponds to Thang’s research 
which was conducted in Sweden and whose sample was from Northern Vietnamese 
women [110]. Another study conducted in China, Sun et al. showed that the ER-, 
PR- and HER2-positive rates in IHC were 60% (758/1,259), 51% (642/1,259) and 
35% (439/1,259), respectively [68]. In a study from Brasil, De Macêdo Andrade 
and colleagues reported a positive proportion of 66.5% and 56.5% for ER and PR, 
respectively [70]. Park et al. found that there is 72.4% for ER-positive and 62.6% 
for PR-positive and 77.7% for Ki67≥14% [69]. In 2009, the study of Onitilo et co-
workers conducted in Wisconsin (USA) showed that the positive ER, PR were 
77.9% and 59.1 %, respectively [100]. Also, hormonal receptors were positive in 
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83.5% of the study population in Italy, compared to the expectation of approximately 
75% [111] and 77% ER-positive [112]. Similar to studies of Onitilo and Clavarezza 
[111], the result of Nadji demonstrated the rate of positive ER and PR are much 
higher than those in our study [21]. However, many studies have shown that the ER-
positive in breast cancer is very different between various ethnicities [113], [114]. In 
addition, the different biological features can be due to various races and regions. 
There are many reports about the estrogen receptor of Vietnamese patients in breast 
cancer which were similar to that of Asian patients and were lower than that in some 
previous studies for Caucasian patients [110], [115]. 
Hormonal receptor status of primary breast cancer is a predicting treatment 
response to postoperative adjuvant systemic endocrine therapy. Therefore, it is very 
important to determine positive ER patients who have good prognoses and will 
receive most benefits from endocrine therapy. 
With regards to the proliferation index, we used 14% as an optimal cut off 
point to divide Ki67 into 2 groups [73]. In this study, the Ki67≥ 14% group 
occupied 81.8% and the figure for Ki67< 14% was 18.2%. Ki67 is an important 
biomarker which has been applied into routine clinical pathological practice. This is 
a prognosis factor which predicts response or resistance to chemotherapy and 
endocrine therapy. The 2013 Saint Gallen Conference indicated that a Ki67 level of 
≥14% could distinguish between luminal A and luminal B-HER2 negative tumours 
in breast carcinoma molecular subtyping [37]. 
5.3.2. Molecular Subtype Breast cancer 
According the Saint Gallen Conference 2013, basing on the expression 
levels of ER, PR, HER2 and the Ki67 proliferation index, the breast carcinoma was 
divided into five subtypes as follows: 
        Molecular Subtypes            ER and/or PgR       HER2      Ki67 Expression 
Luminal A                 Positive         Negative    <14% 
Luminal B-HER2 negative       Positive           Negative    ≥14% 
Luminal B-HER2 positive        Positive          Positive              Any 
HER2 overexpression         Negative          Positive              Any 
Triple negative          Negative          Negative    Any 
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In our research, we have determined the molecular subtypes basing on this 
classification. We found that the luminal A, luminal B-HER2 negative, luminal 
B-HER2 positive, HER2 enriched and triple negative breast cancer were present 
in 16 (at 18.2%), in 24 (at 27.3%), in 9 (at 10.2%), in 20 (at 22.7%) and in 19 
cases (at 21.6%) patients, respectively (Chart 4.4). The luminal B was the most 
common, occupied 38% of all samples. 
 
Chart 5.2: Comparison the distribution of molecular subtypes 
Our result is similar to studies of Sun and co-workers which was conducted 
on Chinese patients in 2015 [68]. El. Fatemi and colleagues also had the same 
result studied on North African women [71]. In another analysis about molecular 
breast cancer subtypes in North-Eastern Brazil, De Macêdo Andrade et al. 
reported that the luminal B subtype was more prevalent (44.6%), followed by 
luminal A (23.8%). Their result is also corresponded to our analysis [70]. 
However, several studies about molecular subtypes from different countries have 
shown different results [9], [69], [72], [73]. The study of Wang and co-workers, 
in 2016 also showed the distribution of subtypes is not absolutely similar to our 
result [116]. The luminal A in our study is lower than those in many previous 
studies from Western countries and Canada [9], [69], [73]. In literature, the 
luminal A is found in 50-72% of breast cancer patients. This subtype has the best 
Nguyen Phuong Thao Tien - HER2 status and molecular subtypes of breast cancer in Central Vietnam 
Ph.D thesis in Clinical Biochemistry and Clinical Proteomics of 
Ph.D School in Life Sciences and Biotechnologies - University of Sassari 
 
50 
    
prognosis with low proliferative index, good differentiation and lowest risk of 
local recurrence and relapse [85], [117], [118]. However, there are different 
results reported in literature regarding this subtype with 34% of Italy, 3.9% of 
Saudi Arabia, 71% of Japan [9], [119], [120]. 
Nowadays, luminal B subtype is divided into 2 groups, included luminal B 
with positive estrogen receptor, negative HER2 receptor, higher Ki-67 value of over 
14% and luminal B with HER2 positive, estrogen negative and progesterone 
negative. Both types of luminal B have worse prognosis than luminal A subtype. 
Many previous studies showed that luminal B subtype is responsible for 10-20% of 
breast cancer patients [121], [122], [123]. In our data, luminal B is found in 37.5%, 
being higher than previous studies but similar to studies on Southern China and on 
North African women [71], [124]. The increase in the prevalence of luminal B 
might be as a result of the high number of HER2-positive cases in this study (Chart 
4.4). In addition, the chart 4.3 showed that the majority of our breast cancer patients 
are detected in late stage of disease with a large tumour which has a positive 
relationship with proliferation index (p<0.001). The vast majority of the large 
tumours in size express a high level of Ki67 (≥14%). Therefore, the application of 
the Ki67 index ≥14% as a cut-off point to distinguish between luminal A and 
luminal B molecular subtypes could increase the rate of luminal B breast cancer and 
could be expression of the bigger size of the tumour when diagnosed and expression 
of late diagnosis. 
In our study, we have accounted 22.7% and 21.6% in HER2 enriched 
subtype and triple negative breast cancer, respectively. Both subtypes are very 
aggressive and have the worst prognostic. These subtypes are always associated 
with a reduction in survival rates. The proportion of HER2 enriched subtype in our 
data is much higher than that in Italy (11%), in USA (7.4%) and in France (4.3%) 
[9], [80], [100]. Our figure for HER2 enriched subtype is also slightly higher than 
that in China (18%) and in South Asia (17.8%) [68], [85]. 
The prevalence of triple negative in our study (21.6%) is similar to 
another studies in Korean (19.9%), in Morocco (23.4%), in Algeria (20.8%) and 
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in black population of the USA (20%) [71], [125], [126]. However, our figure 
for triple negative is higher than that in white population of the USA (9%) in 
studies of Clarke and Howlader [126], [127]. Our result is also higher than 
studies of Kondov (9.3%), Cortet (10.7%), Park (16.2%) and Caldarella (19%) 
which conducted in France, Macedonia, Korea and Italy, respectively [9], [69], 
[72], [80]. The triple negative has a shorter survival time and a higher recurrence 
rate compared to other subtypes. 
We observed the difference in prevalence among our subtypes and those 
reported in the previous studies because breast cancer is known as a heterogeneous 
disease. Therefore, the differences in data may explain the disparities in biological 
features between tumours of patients in many countries. In addition, the 
geography and the ethnicity and environment also play an important role in 
different distribution of molecular subtypes. Even in large countries, the regions 
having different races will have a different distribution of molecular subtypes 
[127], [128]. The HER2-positive tumours are dominant in Asian countries while 
triple negative is frequent in African and black USA population. Our figure for 
triple negative is slightly higher in comparison with that for some Asian countries. 
The luminal A and luminal B are more common in Western countries and white 
USA population [9], [127]. 
Our data have shown that approximately a half of cases in the sample are 
aggressive tumours with bad prognoses. 
5.4. Relationship between HER2 status and prognostic factors 
We have found out the statistically significant difference between the HER2 
status and histologic grade (p <0.001), between the HER2 status and proliferation 
index (p<0.005). Most of the cases in positive HER2 group have a high histologic 
grade and high Ki67. A lot of studies have a similar results to our study [39], [40], 
[43, 53], [55], [129], [130]. In addition, our data showed that there were also 
significantly negative correlation between the HER2 status and the estrogen 
receptor with p <0.001 (Table 4.7). The ER-negative is more frequent in positive 
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HER2 group. Many previous studies reported the correlation between HER2 status 
and the other prognosis [40], [52], [56], [131].  
In our study, we have found out the difference between HER2 status and size 
of tumour (p=0.061), between HER2 status and stage at disease (p=0.057), as well 
as lymph node status (p=0.08). However, those differences are not statistically 
significant. Similar to our results, in the study conducted in Chicago (Illinois, USA), 
Ariga and co-workers showed that there was no correlation between the size of the 
tumour and the age of patients with HER2 positive [53]. 
5.5. Relationship between molecular subtypes and prognostic factors 
Our data showed that there are significant differences between molecular 
subtype and histologic type, histologic grade and proliferation index with p < 0.001 
(table 4.8). The frequent histopathological grade in luminal A was grade II (62.5%) 
while most of the HER2 enriched cases had higher grade (grade III). Besides, the 
study showed a significant difference between subtype and stage at disease with 
p<0.05. The vast majority of the luminal A subtype were in early stage of disease. 
In addition, the chart 4.6 also showed that 50% of tumours less than 2cm in size 
were luminal A subtype and the large tumours (≥5cm) just occupied 6.2% of this 
subtype. Therefore, the characteristics of luminal A in our study were absolutely 
similar to that in previous studies, with small tumour size, low grade, low Ki67 and 
less metastasis [132], [133]. The luminal A subtype has the best prognosis, in 
contrast, luminal B-HER2 positive, triple negative and HER2 enrich subtype have 
the worst prognosis. Even HER2 enriched tumours are more aggressive and have 
poorer prognosis than triple negative [121], [134]. However, the specific therapy 
has changed a lot in recent years. The target therapy has considerable improved the 
prognosis of this subtype. Besides the HER2 subtype, we accounted for a high 
proportion of triple negative breast cancer (Chart 4.4). The table 4.8 showed that the 
majority of our TNBC tumours were invasive ductal carcinoma with high 
histological grade and high Ki-67 expression. Many authors have demonstrated the 
similar results to our data [9], [83], [100], [135]. 
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The HER2 positive subtype was more higher in Vietnamese population 
than Western populations [28]. Therefore, the development of standardized 
HER2 assay is very necessary to identify HER2 gene amplification and using the 
anti-HER2 therapy. 
The distribution of molecular subtypes by age at diagnosis is presented by 
chart 4.5. While luminal A subtype was the most common in women aged 55-60 
years, most cases of luminal B-HER2 negative and HER2 enrich are detected in the 
earlier age group (50-55). Those results correspond with many studies which 
showed that the luminal A occurs in older women than others [72], [85], [123], 
[136], [137]. In particular, in our data, the triple negative subtypes are found in all 
three profiles by age: young adults (35-40), middle-aged (50-55) and older adults 
(aged over 70). This distribution is not similar among the studies [123], [138], 
[139]. This might due to triple negative breast cancer is a heterogeneous disease. 
The TNBC has been shown to be represented according to gene expression profiles 
by different entities. Some of them are able to identify four subtypes and others 
suggest six different groups [67], [123], [140]. 
The luminal B-HER2 positive in our result was extremely prevalent in very 
young women aged between 35-40 like triple subtypes and in middle-aged women 
(50-55) like other subtypes. The study of Li and co-workers conducted in China 
showed that the luminal B-HER2 positive was common at age <50 [141]. 
However, in another study with population-based study from SEER program, Wu 
et al. reported that the luminal B-HER2 enrich occurs at the period from 50 to 64 
years old [142]. The different results of studies show the diversity of biological 
tumour cells.  
The incidence of breast cancer in Vietnam is lower than United States and 
European countries. However, the majority of Vietnamese patients are diagnosed at 
late stage of disease. Therefore, the treatments are more difficult. With the hope to 
detect the breast cancer in earlier stage, we suggest a screening program should be 
done in a more young age as usually done in Western countries, particularly in 
woman with familiar history of breast cancer. 
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5.6. Concordance between IHC and DISH 
The results shown in table 4.10 have demonstrated the high concordance 
between DISH and IHC in evaluating the HER2 gene status in invasive breast 
cancer. The concordances between IHC and DISH in testing HER2 status were 
100% in case of IHC positive or negative. DISH assay is a new technique which is 
fully automatic and whose results could be interpreted by light microscopy. Many 
studies showed that there is a high concordance between DISH and other techniques 
in assessing the HER2 gene amplification [143]. In 2015, Chivukula and colleagues 
observed a concordance rate of 98% between FISH and DISH [144]. A similar to 
Chivukula’s result was obtained in the study of Horii and co-workers, which also 
reported the same concordance of 96.2% [145]. In another experiment, Papouchado 
et al. showed that there is a concordance between FISH and SISH which is similar 
to DISH technique with a result of 98.9% [146].  
In our data, in case of HER2 equivocal in IHC, we found that the 
concordance between IHC and DISH was 25%. The rate of gene amplification of 
HER2 equivocal cases in IHC varied among studies because the overexpression of 
HER2 protein may occur both in the presence or absence of gene amplification 
[147]. Many studies had a similar result to our data. Owens and colleagues, in their 
study, found that 23.3% HER2 gene amplification in FISH seen in IHC (2+) cases 
[148] while in another study, SISH assay was applied in case of HER2 equivocal in 
IHC, Musa et al. reported that the concordance between SISH and IHC is 36.5% 
[87]. Until now, FISH technique always remains a “gold standard” to identify the 
HER2 gene amplification. Many laboratories prefer to use FISH assay to diagnose. 
However, FISH methodology requires a longer time for staining, specialized 
training and fluorescence microscopy analysis. DISH technique has more 
advantages, being recommended as a new assay for evaluating HER2 status. 
However, according to many studies, the concordance between FISH and DISH 
technique is not completely the same. Therefore, in some particular cases, FISH 
technique should be applied in order to have the most precise assessment. It is also a 
very important tool to decide the targeted therapy. 
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6. CONCLUSION 
 
In summary, we assessed the HER2 status and the molecular subtypes in 88 
samples from surgically removed breast cancer in Central Vietnam. 
 The rates of HER2 protein overexpression were 30.7% for 
immunohistochemistry (IHC) 3+ score and 9.1% for IHC 2+ score. 
 Gene amplification by fluorescence in situ hybridization (FISH) was found 
in 25% of tumours with an equivocal score of immunohistochemistry. 
 The prevalence rate of HER2 positive was 32.9%. 
 The concordance between immunohistochemistry and dual in situ 
hybridization (DISH) in testing HER2 status were 100% in case of IHC positive or 
negative and 25% in case of IHC equivocal. 
 The concordance between FISH and DISH in case of equivocal IHC was 100% 
 The luminal B subtype was the most frequent (37.5%) while the 
uncommon belonged to luminal A, at 18.2%. The HER2 enriched and triple 
negative subtype occupied 22.7% and 21.6%, respectively. 
 A significant correlation was found between HER2 status and histological 
grade, estrogen receptor (ER) status and Ki67 proliferation index. 
 A significant correlation was found between molecular subtypes and 
histological stage, type, grade and Ki67. 
We suggest that further investigations should be done with more samples (all 
Vietnamese breast cancer patients, possible within an organized national cancer 
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